Domestic pharma major Cipla has sought approval from Indian regulators to launch experimental coronavirus drug favipiravir in India for treatment of Covid-19 patients.
Under the auspices of Indian Council of Medical Research or ICMR, Cipla will conduct a limited trial prior to marketing the product as Ciplenza.
Mumbai-based Glenmark Pharmaceuticals on Thursday said it has received approval from the Drug Controller General of India to conduct clinical trials of antiviral drug favipiravir on coronavirus patients.
Glenmark said it has received approval for conducting the trial on mild to moderate patients. Globally many drugs are under clinical trials on coronavirus patients to establish their efficacy against Covid-19.